SETD2 and clear cell renal carcinoma: Conversely, loss-of-function mutations in epigenetic modulators such as HMT, SETD2 results in metabolic dysregulations such as aerobic glycolysis and increased TCA cycle metabolite flux as observed in clear cell renal carcinoma [135], which are key features of metabolic rewiring in cancer cells.